THE BURDEN OF CANCER TRIPLE NEGATIVE BREAST CANCER HEAD & NECK CANCER METASTATIC MELANOMA 6 73,870 1 �� -2�� % 1. 2. 3. 4. 5. of breast cancer cases are triple negative (TNBC). TNBC can be more aggressive and difficult to treat compared to other types of breast cancers 1 th people in the U.S. will be diagnosed with melanoma in 2015. Almost 10,000 people in the U.S. are expected to die of melanoma this year 3 most common cancer worldwide and ranked 8th most common cause of cancer death 2 2015 PROJECTED ANNUAL COST FOR CONTINUING TREATMENT IN U.S. 4, 5 $7.8B $1.1B * $1.8B * Represents the total cost of continuing care for all types of breast cancer HOW IS CANCER TREATED? TRADITIONAL METHODS 6 RADIATION SURGERY EMERGING FIELD CHEMOTHERAPY TARGETED THERAPIES Researchers have found Immunotherapies can be In the next 10 years, different ways to help the used as single agents or immunotherapy is body’s own immune they can be combined with projected to form the system recognize cancer other treatments to help backbone for 60% of cells and strengthen its make them more effective all cancer treatment response to fight cancer 6 against certain cancers 7 regimens worldwide 8 IMMUNOTHERAPY IMMUNOPULSE PLATFORM TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER PHASE II SAFETY RESULTS AND ANTI-TUMOR ACTIVITY † ImmunoPulseTM is an investigational platform designed to deliver DNAbased therapeutics directly into the tumor microenvironment to help fight cancer ImmunoPulse™ IL-12 was generally safe and well-tolerated across multiple treatment cycles with no treatment-related serious adverse events reported. The most common treatmentrelated adverse event reported (87%) was mild to moderate pain at the treatment site. Clinical development with ImmunoPulseTM focuses on intratumoral delivery of DNA expressing interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions This proprietary technology employs electroporation, which increases the permeability of the cell membrane, permitting the DNA to enter the cell Preliminary data shows ImmunoPulseTM can generate an initial local immune response as well as a systemic effect and laid the groundwork for expansion into combination therapy approaches TO LEARN MORE... About immunotherapy, visit www.Cancer.org About ImmunoPulseTM, visit www.OncoSec.com �� 31% Best overall response rate 50% Patients with regression of at least one non-treated lesion �� 14% Complete response rate 48% Patients experienced an objective response or disease stabilization † Phase II study evaluated safety and efficacy of ImmunoPulseTM IL-12 in 29 patients with metastatic melanoma using modified RECIST criteria 1. BreastCancer.org. “Triple Negative Breast Cancer.” http://www.breastcancer.org/symptoms/diagnosis/trip_neg. 2. Parfenov M, et. al. “Characterization of HPV and host genome interactions in primary head and neck cancers.” PNAS (2014) 111 (43) 15544-15549. 3. American Cancer Society. “What Are the Key Statistics about Melanoma Skin Cancer?” http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-key-statistics. 4. Mariotto, AB. et. al. “Projections of the Cost of Cancer Care in the United States: 2010–2020.” J Natl Cancer Inst (2011) 103 (2): 117-128. 5. National Cancer Institute. “Cancer Prevalence and Cost of Care Projections.” http://costprojections.cancer.gov/graph.php. 6. American Cancer Society. “Types of Cancer Treatment.” http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/index. 7. American Cancer Society. “What’s New in Cancer Immunotherapy Research?” http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/immunotherapy/immunotherapy-whats-new-immuno-res. 8. Citigroup Inc. “Immunotherapy - The Beginning of the End for Cancer.” https://www.citivelocity.com/citigps/OpArticleDetail.action?recordId=209.